問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Far Eastern Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 220New Taipei CityBanciao

Recruiting Trial

134Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

321Cases

2018-08-24 - 2021-01-29

Phase II

A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)

  • Condition/Disease

    正常收縮分率心臟衰竭(HFpEF)

  • Test Drug

    Vericiguat, BAY 1021189

Participate Sites
4Sites

Terminated4Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2013-07-15 - 2016-01-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-11-16 - 2022-01-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

  • Condition/Disease

    Diabetic kidney disease

  • Test Drug

    BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯
Taipei Medical University Hospital

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2015-11-26 - 2022-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

  • Condition/Disease

    Diabetic kidney disease

  • Test Drug

    BAY 94-8862/ Finerenone

Participate Sites
9Sites

Terminated9Sites

吳麥斯
Taipei Medical University Hospital

Division of Nephrology

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2013-10-31 - 2015-06-30

Phase II

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)

  • Condition/Disease

    Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)

  • Test Drug

    BAY 1021189 immediate-release (IR) tablet

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2013-10-31 - 2015-10-30

Phase II

A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)

  • Condition/Disease

    Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)

  • Test Drug

    BAY 1021189

Participate Sites
5Sites

Terminated5Sites

2006-02-01 - 2007-04-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2015-05-01 - 2017-03-25

Phase III

A randomized, double-blind, active drug-controlled, parallel grouping trial, in patients with severe to very severe chronic obstructive pulmonary disease (COPD), using tiotropium as a benchmark to evaluate oral inhaled tiotropium + olodaterol fixed-dose combination once a day The effect of 52-week treatment on the acute onset of COPD. [DYNAGITO]

  • Condition/Disease

    COPD

  • Test Drug

    Tiotropium + Olodaterol fixed dose combination (FDC) inhalation solution- RESPIMATR Inhaler

Participate Sites
15Sites

Terminated13Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

鍾啟禮
Taipei Medical University Hospital

Division of Thoracic Medicine

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-04-15 - 2017-12-31

Phase III

A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

  • Condition/Disease

    Antidote for dabigatran

  • Test Drug

    Idarucizumab (BI 655075)

Participate Sites
5Sites

Terminated5Sites

1 28 29 30 31 32 33
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB